Morgan, You're right about putting shares on sale at a high price and keep raising that amount as the PPS climbs. By placing shares for sale, they become locked up and unavailable for shorting. TD Ameritrade will allow an ask price of $100 per share, whereas Scottrade places their limit based on a percentage. If everyone who is long on this investment will place their shares for sale, we can greatly limit shares available for shorting. Once this rally tapers off, bashers will be all over this board and the shorting will increase. So lock 'em up now and keep your shares out of Shorty's hands!
Asu, Idera would have to make such information public knowledge. I haven't seen anything on their website referencing shingles.
As far as curing shingles is concerned, that is not likely. As you probably know, shingles is due to reactivation of the virus that causes chickenpox. Once the virus is reactivated decades later in life (60+ y/o), the varicella virus that caused chickenpox as a child is called varicella zoster (AKA herpes zoster) in a mature adult. The virus has been in that person’s body since initial inoculation. Later in life, when the immune system weakens and a stressor occurs, the virus awakens and produces the uncomfortable symptoms. The body then gains a secondary immunity and the virus becomes dormant again.
Since TLR antagonists suppress inflammation associated with autoimmune diseases such as psoriasis, lupus and rheumatoid arthritis, it is possible that inflammation that normally occurs with shingles would be suppressed and the body’s immune system would be strong enough to prevent activation of the virus. While it isn’t really a cure, prevention of activation (as occurs with a vaccine) or rapid reduction of symptoms if treated after presentation of symptoms, the patient would be very grateful to have received treatment. The patient may believe he or she was cured, but reality is the virus returned to a dormant state. Curing diseases is very difficult; most medications simply control diseases and their associated symptoms.
BTW, great alias… I also love the USA!
I don't think there's been a leak of clinical data, although that is a possibility. I think investors are reacting to the disclosed SEC filings from the big boys. It is always comforting to see money flowing into an investment. The more institutional investors jump in, the more retail investors will follow suit and keep the rally going.
Time will tell what the new floor will be. Given the upside potential, these prices are cheap. Investors need to look beyond short-term gains and think of this investment for retirement purposes. A good approach would be to keep trading half of one's shares until the second half are paid for. Having shares on the house that go the distance (most likely acquisition), would make for a nice retirement.
Platinum, You’re right about the importance of the TLR antagonists in blocking an overactive autoimmune response. The currently used biologic agents (TNF inhibitors) that are used to treat psoriasis have a risky safety profile and lose their efficacy with time. Physicians need treatment options, and the TLR antagonists being developed by Idera will not just add such an option, they may become the preferred agent in due time.
While Idera has a nice pipeline of drug candidates and Merck was impressed enough to collaborate on the cancer studies, in my opinion, the psoriasis drugs will initially be the real money makers. Psoriasis is the most prevalent autoimmune disease in the US, affecting 2-3% of the total population. The TLR antagonists being developed by Idera are not only showing promise in psoriasis patients, but the same mechanism of action is used to treat lupus and rheumatoid arthritis. The market potential jumps on those additional indications, not to mention the cancer indication as well.
Investors should take the time to read up on the trial results of IMO-3100 and IMO-8400. Check Idera's website to see their presentation and see how the mechanism of action differs from the current biologic agents.
The only similarity to Enbrel and other TNF inhibitors is the route/method of drug delivery: SQ injection. The big difference and what really matters is the mechanism of action. TNF inhibitors block the activity of specific cytokines, whereas Idera’s TLR antagonists block interaction of complexes by inhibiting the formation of cytokines and the signaling cascades. The TLR antagonists do not affect the activity of normal levels of ctyokines, but do block immune responses linked to diseases that produce multiple cytokines. Simply stated, Idera is suppressing cytokines linked to autoimmune diseases without affecting non-disease/healthy cytokines. Success in the trials will mean that Idera has opened a new avenue for treating autoimmune diseases.
You are correct that there was a better response at the lower dose initially. However, at the end of the 4-week follow-up, 25% (3 of 12) of patients treated with 0.16 mg/kg dose and 31% (4 of 13) with 0.32 mg/kg dose achieved PASI 50 or greater. As more patients are treated in the future, the proper dosing regimen will be found. For now, the safety and efficacy implies that patients can be started at a lower dose and then increased if necessary. As you know from your experience in infectious diseases, patients respond differently to treatment and having the ability to safely double the dosage is a good thing that is welcomed by providers.